Synonym
EE 581; EE-581; EE581;
IUPAC/Chemical Name
(2S)-2-((2R)-2-((S)-2-((S)-2-((R)-2-amino-3-(4-azidophenyl)propanamido)propanamido)-3-(4-hydroxyphenyl)propanamido)-3-((1aR)-1a,2-dihydro-6bH-thiireno[2,3-b]indol-6b-yl)propanamido)-N-((2S,3R)-1-((2R)-2-((1,3-dihydroxybutan-2-yl)amino)-3-mercaptopropanamido)-3-hydroxy-1-oxobutan-2-yl)-6-iminohexanamide
InChi Key
UMMVUDFAAZGEKC-LOWOIFONSA-N
InChi Code
InChI=1S/C49H65N13O11S2/c1-25(53-42(68)33(51)20-28-11-15-30(16-12-28)61-62-52)41(67)56-36(21-29-13-17-31(66)18-14-29)44(70)57-37(22-49-32-8-4-5-9-34(32)58-48(49)75-49)45(71)55-35(10-6-7-19-50)43(69)59-40(27(3)65)47(73)60-46(72)39(24-74)54-38(23-63)26(2)64/h4-5,8-9,11-19,25-27,33,35-40,48,50,54,58,63-66,74H,6-7,10,20-24,51H2,1-3H3,(H,53,68)(H,55,71)(H,56,67)(H,57,70)(H,59,69)(H,60,72,73)/t25-,26?,27+,33+,35-,36-,37+,38?,39-,40-,48+,49?/m0/s1
SMILES Code
C[C@@H](O)[C@H](NC([C@@H](NC([C@H](NC([C@@H](NC([C@@H](NC([C@H](N)Cc1ccc(N=[N+]=[N-])cc1)=O)C)=O)Cc2ccc(O)cc2)=O)CC34c5c(N[C@@H]3S4)cccc5)=O)CCCC=N)=O)C(NC([C@@H](NC(C(O)C)CO)CS)=O)=O
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
Preparing Stock Solutions
The following data is based on the
product
molecular weight
1,076.25
Batch specific molecular weights may vary
from batch to batch
due to the degree of hydration, which will
affect the solvent
volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass |
1 mg |
5 mg |
10 mg |
| 1 mM |
1.15 mL |
5.76 mL |
11.51 mL |
| 5 mM |
0.23 mL |
1.15 mL |
2.3 mL |
| 10 mM |
0.12 mL |
0.58 mL |
1.15 mL |
| 50 mM |
0.02 mL |
0.12 mL |
0.23 mL |
1: Radwan B, Dvorak D, Fenton AA. Impaired cognitive discrimination and discoordination of coupled theta-gamma oscillations in Fmr1 knockout mice. Neurobiol Dis. 2016 Apr;88:125-38. doi: 10.1016/j.nbd.2016.01.003. Epub 2016 Jan 12. PubMed PMID: 26792400; PubMed Central PMCID: PMC4758895.
2: Baytan B, Evim MS, Güler S, Güneş AM, Okan M. Acute Central Nervous System Complications in Pediatric Acute Lymphoblastic Leukemia. Pediatr Neurol. 2015 Oct;53(4):312-8. doi: 10.1016/j.pediatrneurol.2015.03.006. Epub 2015 May 15. PubMed PMID: 26202590.
3: Aso T. [MRI in epilepsy and migraine]. Rinsho Shinkeigaku. 2013;53(11):1097-9. Review. Japanese. PubMed PMID: 24291890.
4: Grupe DW, Nitschke JB. Uncertainty is associated with biased expectancies and heightened responses to aversion. Emotion. 2011 Apr;11(2):413-24. doi: 10.1037/a0022583. PubMed PMID: 21500909; PubMed Central PMCID: PMC3086262.
5: Winrow CJ, Gotter AL, Cox CD, Doran SM, Tannenbaum PL, Breslin MJ, Garson SL, Fox SV, Harrell CM, Stevens J, Reiss DR, Cui D, Coleman PJ, Renger JJ. Promotion of sleep by suvorexant-a novel dual orexin receptor antagonist. J Neurogenet. 2011 Mar;25(1-2):52-61. doi: 10.3109/01677063.2011.566953. Epub 2011 Apr 8. Erratum in: J Neurogenet. 2016 Sep - Dec;30(3-4):316. PubMed PMID: 21473737.
6: Medina-Ceja L, Ventura-Mejía C. Differential effects of trimethylamine and quinine on seizures induced by 4-aminopyridine administration in the entorhinal cortex of vigilant rats. Seizure. 2010 Oct;19(8):507-13. doi: 10.1016/j.seizure.2010.07.009. Epub 2010 Aug 3. PubMed PMID: 20685138.
7: Xia Y, Lai Y, Lei L, Liu Y, Yao D. Left hemisphere predominance of pilocarpine-induced rat epileptiform discharges. J Neuroeng Rehabil. 2009 Nov 30;6:42. doi: 10.1186/1743-0003-6-42. PubMed PMID: 19948024; PubMed Central PMCID: PMC2794280.
8: Sanchez JC, Mareci TH, Norman WM, Principe JC, Ditto WL, Carney PR. Evolving into epilepsy: Multiscale electrophysiological analysis and imaging in an animal model. Exp Neurol. 2006 Mar;198(1):31-47. Epub 2006 Jan 4. PubMed PMID: 16386735.
9: Praamstra P, Seiss E. The neurophysiology of response competition: motor cortex activation and inhibition following subliminal response priming. J Cogn Neurosci. 2005 Mar;17(3):483-93. PubMed PMID: 15814007.
10: Strobel A, Debener S, Anacker K, Müller J, Lesch KP, Brocke B. Dopamine D4 receptor exon III genotype influence on the auditory evoked novelty P3. Neuroreport. 2004 Oct 25;15(15):2411-5. PubMed PMID: 15640766.
11: Srikant CB, Murthy KK, Escher EE, Patel YC. Photoaffinity labeling of the somatostatin receptor: identification of molecular subtypes. Endocrinology. 1992 May;130(5):2937-46. PubMed PMID: 1349280.
12: Patel YC, Murthy KK, Escher EE, Banville D, Spiess J, Srikant CB. Mechanism of action of somatostatin: an overview of receptor function and studies of the molecular characterization and purification of somatostatin receptor proteins. Metabolism. 1990 Sep;39(9 Suppl 2):63-9. PubMed PMID: 1976223.
